JP2025508695A5 - - Google Patents

Info

Publication number
JP2025508695A5
JP2025508695A5 JP2024547460A JP2024547460A JP2025508695A5 JP 2025508695 A5 JP2025508695 A5 JP 2025508695A5 JP 2024547460 A JP2024547460 A JP 2024547460A JP 2024547460 A JP2024547460 A JP 2024547460A JP 2025508695 A5 JP2025508695 A5 JP 2025508695A5
Authority
JP
Japan
Prior art keywords
therapy
kit according
approximately
immune checkpoint
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508695A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/062434 external-priority patent/WO2023154895A1/en
Publication of JP2025508695A publication Critical patent/JP2025508695A/ja
Publication of JP2025508695A5 publication Critical patent/JP2025508695A5/ja
Pending legal-status Critical Current

Links

JP2024547460A 2022-02-11 2023-02-10 がん治療における免疫チェックポイント阻害剤対化学療法の有効性のための予測バイオマーカーとしての腫瘍変異負荷の使用 Pending JP2025508695A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263309449P 2022-02-11 2022-02-11
US63/309,449 2022-02-11
US202263335079P 2022-04-26 2022-04-26
US63/335,079 2022-04-26
PCT/US2023/062434 WO2023154895A1 (en) 2022-02-11 2023-02-10 Use of tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus chemotherapy effectiveness in cancer treatment

Publications (2)

Publication Number Publication Date
JP2025508695A JP2025508695A (ja) 2025-04-10
JP2025508695A5 true JP2025508695A5 (https=) 2026-02-16

Family

ID=87565160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547460A Pending JP2025508695A (ja) 2022-02-11 2023-02-10 がん治療における免疫チェックポイント阻害剤対化学療法の有効性のための予測バイオマーカーとしての腫瘍変異負荷の使用

Country Status (4)

Country Link
US (1) US20250146078A1 (https=)
EP (1) EP4476368A4 (https=)
JP (1) JP2025508695A (https=)
WO (1) WO2023154895A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026060295A1 (en) * 2024-09-12 2026-03-19 Omniseq, Inc. Cancer testis antigen burden (ctab) as a biomarker of tumor-associated antigens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3038712A1 (en) * 2016-10-06 2018-04-12 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP3601355A1 (en) * 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
WO2021092221A1 (en) * 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy

Similar Documents

Publication Publication Date Title
Sen et al. Targeting DNA damage repair in small cell lung cancer and the biomarker landscape
Elias Small cell lung cancer: state-of-the-art therapy in 1996
Lukan et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status
JP2019535237A5 (https=)
JP2025508695A5 (https=)
Shi et al. Impact of Adjuvant chemoradiotherapy on survival of resected pancreatic adenocarcinoma cancer: a Surveillance, Epidemiology and End Results (SEER) Analysis
Inno et al. Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?
Jeene et al. The role of definitive chemoradiation in patients with non-metastatic oesophageal cancer
Uramoto et al. Resistance to gefitinib
Xian et al. Mechanistic insights into genomic structure and functions of a novel oncogene YEATS4
Gulliver et al. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer
Filipits et al. Predictive markers in the adjuvant therapy of non-small cell lung cancer
MM Basso et al. Advances in the treatment of triple-negative early breast cancer
JP2023515190A5 (https=)
Jethwa et al. A critical review of the role of local therapy for oligometastatic gastrointestinal cancer
Li et al. Advancements of the CRISPR/Cas9 System in the Treatment of Liver Cancer
Alshimerry et al. Genetic Study of Chemokine Ligand 1 in Colorectal Carcinoma using Quantitative Real-Time PCR
Toy et al. Defektif Homolog Rekombinasyon DNA Tamiri ve PARP İnhibisyonu Arasındaki Sentetik Letal Etkileşim
Curran Jr Therapy of limited stage small cell lung cancer
Joseph et al. Genetic evidence that a gut commensal bacterium can cause colorectal cancer
Esmat et al. Next Generation Sequencing (NGS) in Relapsed/Refractory HPV Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Reveals Diverse Genomic Alterations and Potential Targets of Therapy
Crymes et al. 1188P Landscape of Delta-like-ligand 3 (DLL3) expression across neuroendocrine neoplasms (NENs)
Dadi et al. Antibody treatments for digestive cancers: Past, present, and future
Türkel et al. Investigation of systemic treatment responses and prognostic factors in metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs)
Palumbo et al. Of magic bullets, multiple targets, and artificial intelligence. Are we all set to defeat cancer?